PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 21695255-8 2011 These studies demonstrate that rapamycin might be an effective therapeutic for human ovarian endometrioid patients with dysregulated Wnt/beta-catenin and Pten/PI3K signaling. Sirolimus 31-40 phosphatase and tensin homolog Homo sapiens 154-158 21360661-3 2011 Rapamycin has been reported to be effective in the management of other conditions associated with PTEN mutation. Sirolimus 0-9 phosphatase and tensin homolog Homo sapiens 98-102 21730367-6 2011 Furthermore, rapamycin lowered the IC50s for doxorubicin, etoposide and 4HT in the cells which expressed Akt-1(CA), demonstrating a potential improved method for treating certain breast cancers which have deregulated PI3K/PTEN/Akt/mTOR signaling. Sirolimus 13-22 phosphatase and tensin homolog Homo sapiens 223-227 21168265-7 2011 We also present data herein that PTEN is an important contributor to resveratrol"s growth suppressive effects and its potentiation of rapamycin in this therapeutic scenario, as resveratrol"s suppression of rapamycin-mediated induction of P-AKT is both PTEN-dependent and -independent. Sirolimus 134-143 phosphatase and tensin homolog Homo sapiens 33-37 21168265-7 2011 We also present data herein that PTEN is an important contributor to resveratrol"s growth suppressive effects and its potentiation of rapamycin in this therapeutic scenario, as resveratrol"s suppression of rapamycin-mediated induction of P-AKT is both PTEN-dependent and -independent. Sirolimus 206-215 phosphatase and tensin homolog Homo sapiens 33-37 20863555-10 2010 Sensitivity to rapamycin was independent of PTEN and Akt status. Sirolimus 15-24 phosphatase and tensin homolog Homo sapiens 44-48 19917848-5 2010 TSC2 and PTEN are two key inhibitors of the Akt/mammalian target of rapamycin (mTOR) pathway and the specific inhibition of mTOR with rapamycin or RAD001 inhibited cell proliferation of PET cell lines. Sirolimus 68-77 phosphatase and tensin homolog Homo sapiens 9-13 20933441-5 2010 DC-specific Pten targeting in vivo caused the expansion of CD8(+) and CD103(+) cDC numbers, which was reversible by rapamycin. Sirolimus 116-125 phosphatase and tensin homolog Homo sapiens 12-16 20566381-1 2010 Inhibition of mTOR by rapamycin has been shown to suppress seizures in TSC/PTEN genetic models. Sirolimus 22-31 phosphatase and tensin homolog Homo sapiens 75-79 19211884-6 2009 Here, we report that rapamycin, a specific inhibitor of mammalian target of rapamycin complex 1 (mTORC1), can prevent and reverse neuronal hypertrophy, resulting in the amelioration of a subset of PTEN-associated abnormal behaviors, providing evidence that the mTORC1 pathway downstream of PTEN is critical for this complex phenotype. Sirolimus 21-30 phosphatase and tensin homolog Homo sapiens 197-201 19261747-4 2009 Furthermore, the synergistic effects of p53 and Pten deletion are mediated by deregulation of mammalian target of rapamycin (mTOR) signaling, consistent with the ability of rapamycin to block bladder tumorigenesis in preclinical studies. Sirolimus 114-123 phosphatase and tensin homolog Homo sapiens 48-52 19211884-6 2009 Here, we report that rapamycin, a specific inhibitor of mammalian target of rapamycin complex 1 (mTORC1), can prevent and reverse neuronal hypertrophy, resulting in the amelioration of a subset of PTEN-associated abnormal behaviors, providing evidence that the mTORC1 pathway downstream of PTEN is critical for this complex phenotype. Sirolimus 21-30 phosphatase and tensin homolog Homo sapiens 290-294 19139116-5 2009 Similar AKT-dependent regulation of rapamycin responsiveness was shown in a second myeloma model: the PTEN-null OPM-2 cell line transfected with wild-type PTEN. Sirolimus 36-45 phosphatase and tensin homolog Homo sapiens 102-106 19139116-5 2009 Similar AKT-dependent regulation of rapamycin responsiveness was shown in a second myeloma model: the PTEN-null OPM-2 cell line transfected with wild-type PTEN. Sirolimus 36-45 phosphatase and tensin homolog Homo sapiens 155-159 19115995-5 2008 The expression levels of PTEN- and P27kip1- mRNA were up-regulated, and the mTOR- and cyclinD1- mRNA were down-regulated in K562 cells after the cells transfected with wild type PTEN gene and treated with rapamycin. Sirolimus 205-214 phosphatase and tensin homolog Homo sapiens 178-182 17805960-2 2008 Pre-clinical studies that used breast cancer cell lines have suggested that p-Akt or p-S6K1 expressing tumors, as well as PTEN negative tumors, were sensitive to rapamycin. Sirolimus 162-171 phosphatase and tensin homolog Homo sapiens 122-126 18332865-2 2008 Cells transfected with a mutant PTEN gene lacking both lipid and protein phosphatase activities were more resistant to doxorubicin than cells transfected with the PTEN mutant lacking lipid phosphatase activity indicating that the protein phosphatase activity of PTEN was also important in controlling the sensitivity to doxorubicin, while no difference was observed between the lipid (G129E) and lipid and protein (C124S) phosphatase PTEN mutants in terms of sensitivity to rapamycin. Sirolimus 474-483 phosphatase and tensin homolog Homo sapiens 32-36 18332865-3 2008 A synergistic inhibitory interaction was observed when doxorubicin was combined with rapamycin in the phosphatase-deficient PTEN-transfected cells. Sirolimus 85-94 phosphatase and tensin homolog Homo sapiens 124-128 18431376-0 2008 Rapamycin treatment for a child with germline PTEN mutation. Sirolimus 0-9 phosphatase and tensin homolog Homo sapiens 46-50 18215105-3 2008 METHODS AND FINDINGS: Based on preclinical evidence that phosphatase and tensin homolog deleted on Chromosome 10 (PTEN) loss sensitizes tumors to the inhibition of mammalian target of rapamycin (mTOR), we conducted a proof-of-concept Phase I neoadjuvant trial of rapamycin in patients with recurrent glioblastoma, whose tumors lacked expression of the tumor suppressor PTEN. Sirolimus 184-193 phosphatase and tensin homolog Homo sapiens 114-118 18303120-6 2008 Treatment with rapamycin [a specific inhibitor of mammalian target of rapamycin complex 1 (mTORC1)] inhibited the increased PTEN expression and partially restored insulin-stimulated glucose transport and Akt activation to insulin-resistant cells. Sirolimus 15-24 phosphatase and tensin homolog Homo sapiens 124-128 16885364-4 2006 Nonetheless, loss of even one PTEN allele resulted in lymphomas that were resistant to conventional chemotherapy yet sensitive to rapamycin/chemotherapy combinations. Sirolimus 130-139 phosphatase and tensin homolog Homo sapiens 30-34 16199861-5 2005 In archived material from 12 human GBM tumors, PTEN status was a predictor of activation of the Akt-mTOR-S6K1 pathway and of FLIP(S) levels, while in xenografted human GBM, activation status of the PTEN-Akt-mTOR pathway distinguished the tumors inherently sensitive to TRAIL from those which could be sensitized by the mTOR inhibitor rapamycin. Sirolimus 334-343 phosphatase and tensin homolog Homo sapiens 47-51 15367412-6 2004 The PTEN-negative cell line displayed greater sensitivity to the growth inhibitory effects of the PI3K inhibitor, LY294002 and rapamycin, an inhibitor of the PI3K/Akt downstream mediator mTOR, compared with the PTEN-positive cell lines. Sirolimus 127-136 phosphatase and tensin homolog Homo sapiens 4-8 33319180-5 2020 Rapamycin inhibited mTORC1 and PTEN, but augmented mTORC2 with restoration of miRNA-302a under diabetic conditions. Sirolimus 0-9 phosphatase and tensin homolog Homo sapiens 31-35 12939469-3 2003 Some investigators have hypothesized that loss of the PTEN tumor suppressor may sensitize tumor cells to the antiproliferative activity of rapamycin because PTEN loss leads to activation of the mTOR pathway. Sirolimus 139-148 phosphatase and tensin homolog Homo sapiens 54-58 12939469-6 2003 This effect is independent of PTEN status because PTEN-positive ECC-1 cells are as sensitive to rapamycin as PTEN-null Ishikawa and Hec-1B cells, suggesting that rapamycin may be effective against a broad range of endometrial cancers. Sirolimus 96-105 phosphatase and tensin homolog Homo sapiens 50-54 12939469-6 2003 This effect is independent of PTEN status because PTEN-positive ECC-1 cells are as sensitive to rapamycin as PTEN-null Ishikawa and Hec-1B cells, suggesting that rapamycin may be effective against a broad range of endometrial cancers. Sirolimus 96-105 phosphatase and tensin homolog Homo sapiens 50-54 34902358-5 2022 We determined that the knockdown of Maf1 promoted the survival of RGCs and their axon regeneration through altering the activity of the PTEN/mTOR pathway, which could be blocked by rapamycin. Sirolimus 181-190 phosphatase and tensin homolog Homo sapiens 136-140 33910008-1 2021 Recent studies have demonstrated that selective activation of mammalian target of rapamycin complex 1 (mTORC1) in the cerebellum by deletion of the mTORC1 upstream repressors TSC1 or phosphatase and tensin homolog (PTEN) in Purkinje cells (PCs) causes autism-like features and cognitive deficits. Sirolimus 82-91 phosphatase and tensin homolog Homo sapiens 183-213 33910008-1 2021 Recent studies have demonstrated that selective activation of mammalian target of rapamycin complex 1 (mTORC1) in the cerebellum by deletion of the mTORC1 upstream repressors TSC1 or phosphatase and tensin homolog (PTEN) in Purkinje cells (PCs) causes autism-like features and cognitive deficits. Sirolimus 82-91 phosphatase and tensin homolog Homo sapiens 215-219 12414639-6 2002 Treatment of PC-3 PTEN-negative cells with rapamycin inhibited 70-kDa S6 kinase and increased the proliferative response of these cells to doxorubicin, so that it was comparable with the responses of PTEN-positive DU-145 cells and the PC-3-transfected cells. Sirolimus 43-52 phosphatase and tensin homolog Homo sapiens 18-22 12030785-6 2001 In addition, the status of ATM, p53, PTEN/Akt and 14-3-3 are also associated with rapamycin sensitivity. Sirolimus 82-91 phosphatase and tensin homolog Homo sapiens 37-41 10749120-4 2000 LY294002 and rapamycin also inhibit growth factor- and mitogen-induced secretion of vascular endothelial growth factor, the product of a known HIF-1 target gene, thus linking the PI3K/PTEN/AKT/FRAP pathway, HIF-1, and tumor angiogenesis. Sirolimus 13-22 phosphatase and tensin homolog Homo sapiens 184-188 34003330-7 2021 Mechanistically, LKB1 directly binds and phosphorylates phosphatase and tensin homolog (PTEN), an upstream regulator of mammalian target of rapamycin complex 1 (mTORC1), which is independent of AMP-activated protein kinase (AMPK). Sirolimus 140-149 phosphatase and tensin homolog Homo sapiens 88-92 33532886-0 2021 Treatment of Immune Dysregulation Due to a PTEN Variant with Sirolimus. Sirolimus 61-70 phosphatase and tensin homolog Homo sapiens 43-47 33141044-12 2021 In the combination of rapamycin with AZD3463, the expression of CDKN1B, PTEN, FOXO3, and APC genes increases, and the expression of PRKCB and PIK3CG genes decreases. Sirolimus 22-31 phosphatase and tensin homolog Homo sapiens 72-76 33319180-7 2020 We conclude that rapamycin attenuates reperfusion injury in diabetic heart through inhibition of PTEN and mTORC1 with restoration of miR-302a-mTORC2 signaling. Sirolimus 17-26 phosphatase and tensin homolog Homo sapiens 97-101 32737433-9 2020 Moreover, loss of Smurf1 abolishes the aberrant regulation of PTEN, causing negative feedback on PI3K/Akt/mTOR signaling pathway, and thus leading to rescue of tumor sensitivity to rapamycin in an orthotopic GBM model. Sirolimus 181-190 phosphatase and tensin homolog Homo sapiens 62-66 32062191-0 2020 Rapamycin inhibits B-cell activating factor (BAFF)-stimulated cell proliferation and survival by suppressing Ca2+-CaMKII-dependent PTEN/Akt-Erk1/2 signaling pathway in normal and neoplastic B-lymphoid cells. Sirolimus 0-9 phosphatase and tensin homolog Homo sapiens 131-135 31807781-2 2020 The condition is caused by a mutation in the phosphatase and tensin homolog (PTEN) gene, which results in dysregulation of the mammalian target of rapamycin pathway. Sirolimus 147-156 phosphatase and tensin homolog Homo sapiens 77-81 32062191-5 2020 In addition, rapamycin blocked hsBAFF-stimulated B-cell proliferation and survival by preventing hsBAFF from inactivating PTEN and activating the Akt-Erk1/2 pathway. Sirolimus 13-22 phosphatase and tensin homolog Homo sapiens 122-126 32062191-6 2020 Overexpression of wild type PTEN or ectopic expression of dominant negative Akt potentiated rapamycin"s suppression of hsBAFF-induced Erk1/2 activation and proliferation/viability in Raji cells. Sirolimus 92-101 phosphatase and tensin homolog Homo sapiens 28-32 32062191-9 2020 The results indicate that rapamycin inhibits BAFF-stimulated B-cell proliferation and survival by blunting mTORC1/2-mediated [Ca2+]i elevations and suppressing Ca2+-CaMKII-dependent PTEN/Akt-Erk1/2 signaling pathway. Sirolimus 26-35 phosphatase and tensin homolog Homo sapiens 182-186 31896113-12 2020 The KHE pattern of expression [PTEN (-), TSC2 (-), p-mTOR (+), p-P70S6K (+), and p-4EBP1 (+)] suggested that sirolimus may be a good therapeutic choice. Sirolimus 109-118 phosphatase and tensin homolog Homo sapiens 31-35 27029073-4 2016 To overcome this problem, CH12 was combined with the mTOR inhibitor rapamycin, leading to a synergistic inhibitory effect on EGFRvIII+PTEN- GBM in vivo. Sirolimus 68-77 phosphatase and tensin homolog Homo sapiens 134-138 29844707-2 2018 PTEN mutation in NSCLC may be sensitizing to analogs of rapamycin such as everolimus or temsirolimus, but more investigation is needed. Sirolimus 56-65 phosphatase and tensin homolog Homo sapiens 0-4 26992888-14 2016 Here we have shown that loss of Pten leads to aberrant migration, which can be prevented but not reversed by treatment with rapamycin, a mTor inhibitor. Sirolimus 124-133 phosphatase and tensin homolog Homo sapiens 32-36 31350329-0 2019 A Pilot Study of Sirolimus in Subjects with Cowden Syndrome or Other Syndromes Characterized by Germline Mutations in PTEN. Sirolimus 17-26 phosphatase and tensin homolog Homo sapiens 118-122 31240704-3 2019 Similarly, rapamycin (Rapa) and shRaptor block suppression of PTEN by high glucose. Sirolimus 11-20 phosphatase and tensin homolog Homo sapiens 62-66 31240704-3 2019 Similarly, rapamycin (Rapa) and shRaptor block suppression of PTEN by high glucose. Sirolimus 22-26 phosphatase and tensin homolog Homo sapiens 62-66 30154635-10 2018 Pain secondary to PTEN hamartoma responded poorly to percutaneous sclerosant injection, but demonstrated improvement with sirolimus. Sirolimus 122-131 phosphatase and tensin homolog Homo sapiens 18-22 26229595-8 2015 In cases of facial overgrowth, which involve PTEN/Akt/TOR dysregulation, sirolimus could be used for limiting cell overgrowth. Sirolimus 73-82 phosphatase and tensin homolog Homo sapiens 45-49 24764583-8 2014 Moreover, phosphoinositide 3-kinase (PI3K) pathway inhibition using the AKT inhibitor MK-2206 or rapamycin resulted in decreased PD-L1 expression, further linking PTEN and PI3K signaling to PD-L1 regulation. Sirolimus 97-106 phosphatase and tensin homolog Homo sapiens 163-167 23989949-5 2013 Moreover, PTEN-deficient bladder cancer cells were less sensitive to rapamycin than cells expressing wild-type PTEN, and rapamycin strikingly induced Akt activation in the absence of functional PTEN. Sirolimus 69-78 phosphatase and tensin homolog Homo sapiens 10-14 23989949-5 2013 Moreover, PTEN-deficient bladder cancer cells were less sensitive to rapamycin than cells expressing wild-type PTEN, and rapamycin strikingly induced Akt activation in the absence of functional PTEN. Sirolimus 121-130 phosphatase and tensin homolog Homo sapiens 10-14 22184110-0 2012 Unrestrained mammalian target of rapamycin complexes 1 and 2 increase expression of phosphatase and tensin homolog deleted on chromosome 10 to regulate phosphorylation of Akt kinase. Sirolimus 33-42 phosphatase and tensin homolog Homo sapiens 84-114 22184110-5 2012 To explore the mechanism of PTEN regulation, we used rapamycin and constitutively active mTOR to show that TORC1 increases the expression of PTEN mRNA and protein. Sirolimus 53-62 phosphatase and tensin homolog Homo sapiens 141-145 24603487-6 2014 PTEN and p-Akt downregulation could be abrogated by both the PI3K inhibitor LY294002 and the mTOR inhibitor rapamycin. Sirolimus 108-117 phosphatase and tensin homolog Homo sapiens 0-4 22137317-3 2012 Compared with either drug alone, dexamethasone+rapamycin showed significantly greater apoptosis and cell cycle arrest in some cell lines, and was more frequently seen in T-lineage cell lines with PTEN mutation. Sirolimus 47-56 phosphatase and tensin homolog Homo sapiens 196-200 23139750-11 2012 To determine the significance of Pten status for treatment with the mTOR inhibitor rapamycin we treated 5 MPNST cell lines with rapamycin. Sirolimus 83-92 phosphatase and tensin homolog Homo sapiens 33-37